- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05257408
진행성, 백금 내성, 고도 상피성 난소암, 원발성 복막암 또는 나팔관암에서 Nab-Paclitaxel과 병용하는 이완제
진행성, 백금 내성, 고급 상피성 난소암, 원발성 복막암 또는 나팔관암(ROSELLA)에서 Nab-파클리탁셀과 Nab-파클리탁셀 단독 요법의 병용 요법에 대한 3상 연구
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
연구 개요
상태
상세 설명
As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel.
Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Gyeonggi-do, 대한민국, 10408
- Site 397
-
Seoul, 대한민국, 03080
- Site 399
-
Seoul, 대한민국, 03722
- Site 398
-
Seoul, 대한민국, 05505
- Site 403
-
Seoul, 대한민국, 06273
- Site 400
-
Seoul, 대한민국, 06351
- Site 396
-
Seoul, 대한민국, 08308
- Site 402
-
Seoul, 대한민국, 42601
- Site 409
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85016
- Site 318
-
Tucson, Arizona, 미국, 85719
- Site 277
-
-
California
-
Irvine, California, 미국, 92618
- Site 350
-
La Jolla, California, 미국, 92093
- Site 364
-
Palo Alto, California, 미국, 94304
- Site 150
-
San Francisco, California, 미국, 94109
- Site 278
-
San Francisco, California, 미국, 94143
- Site 014
-
Solvang, California, 미국, 93463
- Site 316
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- Site 032
-
-
Florida
-
Miami Beach, Florida, 미국, 33140
- Site 335
-
Weston, Florida, 미국, 33331
- Site 042
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Site 009
-
Atlanta, Georgia, 미국, 30342
- Site 272
-
Gainesville, Georgia, 미국, 30548
- Site 372
-
Savannah, Georgia, 미국, 31405
- Site 291
-
-
Illinois
-
Evanston, Illinois, 미국, 60201
- Site 315
-
Hinsdale, Illinois, 미국, 60521
- Site 314
-
Urbana, Illinois, 미국, 61801
- Site 346
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46260
- Site 339
-
-
Kansas
-
Overland Park, Kansas, 미국, 66211
- Site 200
-
Overland Park, Kansas, 미국, 66211
- Site 334
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40241
- Site 279
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Site 128
-
-
New Jersey
-
New Brunswick, New Jersey, 미국, 08901
- Site 288
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87131
- Site 292
-
-
New York
-
Flushing, New York, 미국, 11355
- Site 275
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45242
- Site 298
-
Cincinnati, Ohio, 미국, 45459
- Site 304
-
-
Oregon
-
Portland, Oregon, 미국, 97210
- Site 280
-
Portland, Oregon, 미국, 97213
- Site 317
-
Portland, Oregon, 미국, 97239
- Site 049
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, 미국, 18015
- Site 337
-
Pittsburgh, Pennsylvania, 미국, 15213
- Site 127
-
-
South Dakota
-
Rapid City, South Dakota, 미국, 57701
- Site 276
-
-
Tennessee
-
Germantown, Tennessee, 미국, 38138
- Site 368
-
Nashville, Tennessee, 미국, 37203
- Site 281
-
-
Texas
-
Austin, Texas, 미국, 78731
- Site 229
-
Bedford, Texas, 미국, 76022
- Site 312
-
Fort Worth, Texas, 미국, 76104
- Site 297
-
San Antonio, Texas, 미국, 78240
- Site 392
-
The Woodlands, Texas, 미국, 77380
- Site 301
-
-
Virginia
-
Norfolk, Virginia, 미국, 23502
- Site 300
-
Richmond, Virginia, 미국, 23298
- Site 365
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- Site 121
-
-
-
-
-
Aalst, 벨기에, 9300
- Site 328
-
Brussels, 벨기에, B- 1200
- Site 109
-
Charleroi, 벨기에, 6000
- Site 326
-
Hasselt, 벨기에, 3500
- Site 325
-
Leuven, 벨기에, 3000
- Site 108
-
Liège, 벨기에, B-4000
- Site 327
-
-
-
-
-
Porto Alegre, 브라질, 90035-001
- Site 421
-
-
Brasília - DF
-
Brasília, Brasília - DF, 브라질, 70297-400
- Site 424
-
-
Ceará
-
Fortaleza, Ceará, 브라질, 60170-170
- Site 382
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, 브라질, 41950-640
- Site 384
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, 브라질, 30210-040
- Site 383
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, 브라질, 59062-000
- Site 390
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, 브라질, 22250-905
- Site 380
-
-
São Paulo
-
São Paulo, São Paulo, 브라질, 01321001
- Site 376
-
São Paulo, São Paulo, 브라질, 01327-001
- Site 389
-
São Paulo, São Paulo, 브라질, 01409-002
- Site 413
-
São Paulo, São Paulo, 브라질, 01509-900
- Site 374
-
São Paulo, São Paulo, 브라질, 01509010
- Site 001
-
-
-
-
-
Badalona, 스페인, 08916
- Site 349
-
San Sebastián, 스페인, 20014
- Site 311
-
Valencia, 스페인, 46026
- Site 330
-
-
-
-
Buenos Aires
-
CABA, Buenos Aires, 아르헨티나, C1280AEB
- Site 393
-
Ciudad Autonoma de Buenos Aire, Buenos Aires, 아르헨티나, C1426ANZ
- Site 381
-
-
Córdoba Province
-
Córdoba, Córdoba Province, 아르헨티나, X5004FHP
- Site 415
-
Córdoba, Córdoba Province, 아르헨티나, X5008 HHW
- Site 401
-
Córdoba, Córdoba Province, 아르헨티나, X5016
- Site 395
-
-
Mendoza Province
-
Mendoza, Mendoza Province, 아르헨티나, M5500AYB
- Site 404
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, 아르헨티나, 2000
- Site 391
-
Rosario, Santa Fe Province, 아르헨티나, S2000KDS
- Site 412
-
-
-
-
-
Cheltenham, 영국, GL53 7AN
- Site 366
-
London, 영국, NW1 2PG
- Site 055
-
Manchester, 영국, M20 4BX
- Site 344
-
Northwood, 영국, HA6 2RN
- Site 345
-
-
East Sussex
-
Brighton, East Sussex, 영국, BN2 1ES
- Site 367
-
-
Somerset
-
Taunton, Somerset, 영국, TA1 5DA
- Site 351
-
-
-
-
-
Haifa, 이스라엘, 3436212
- Site 309
-
Jerusalem, 이스라엘, 911201
- Site 080
-
Tel Aviv, 이스라엘, 6423906
- Site 203
-
-
-
-
-
Catania, 이탈리아, 95126
- Site 321
-
Legnago, 이탈리아, 37045
- Site 320
-
Milan, 이탈리아, 20141
- Site 122
-
Pavia, 이탈리아, 27100
- Site 295
-
Roma, 이탈리아, 161
- Site 161
-
Rome, 이탈리아, 00168
- Site 124
-
Torino, 이탈리아, 10128
- Site 293
-
Treviso, 이탈리아, 31100
- Site 319
-
-
-
-
Ontario
-
Toronto, Ontario, 캐나다, M4N 3M5
- Site 117
-
-
Quebec
-
Montreal, Quebec, 캐나다, H4A 3J1
- Site 273
-
-
-
-
-
Gdynia, 폴란드, 81-519
- Site 341
-
Poznan, 폴란드, 61-886
- Site 331
-
Siedlce, 폴란드, 08-110
- Site 329
-
-
-
-
-
Lille, 프랑스, 59020
- Site 306
-
Montpellier, 프랑스, 34298
- Site 347
-
Nancy, 프랑스, 54100
- Site 307
-
Nice, 프랑스, 06189
- Site 310
-
Paris, 프랑스, 75015
- Site 289
-
Plérin, 프랑스, 22190
- Site 323
-
-
-
-
-
Budapest, 헝가리, 1122
- Site 322
-
Debrecen, 헝가리, 4032
- Site 290
-
Győr, 헝가리, 9024
- Site 348
-
-
-
-
New South Wales
-
St Leonards, New South Wales, 호주, 2065
- Site 426
-
-
Queensland
-
Benowa, Queensland, 호주, 4217
- Site 417
-
-
Victoria
-
Melbourne, Victoria, 호주, 3000
- Site 414
-
Melbourne, Victoria, 호주, 3128
- Site 419
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Signed and dated Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to study-specific screening procedures.
- Confirmed histologic diagnosis of high-grade (Grade 3) serous, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
- Patients must have platinum-resistant disease (defined as RECIST v1.1 defined progression <6 months from completion of a platinum-containing therapy).
- Must consent to provide archival tumor-tissue block or slides. Patients may consent to an optional tumor biopsy if archival tumor is unavailable.
- Has a life expectancy of ≥3 months.
- At least one lesion that meets the definition of measurable disease by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Able to comply with protocol requirements.
- Able to swallow and retain oral medication and does not have uncontrolled emesis.
- Received at least 1 but ≤3 lines of prior systemic anticancer therapy and at least 1 prior line of platinum therapy and prior treatment with bevacizumab is required.
- Has adequate organ function meeting the following laboratory-test criteria: Absolute neutrophil count (ANC) ≥1500 cells/mm^3, Platelet count ≥100,000/mm^3, Hemoglobin ≥9 g/dL, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in context of liver metastases, Total bilirubin ≤1.5 × ULN, and Albumin ≥3 g/dL, and creatinine clearance >40 mL/min/1.73 m^2 (measured or estimated).
- Negative pregnancy test for patients of childbearing potential; patients of childbearing potential must agree to use highly effective contraceptive method(s); hormonal contraceptives are not allowed.
- Coronavirus disease (COVID-19) approved vaccines are accepted concomitant medications when recommended by the Investigator.
Exclusion Criteria:
- Has clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that has not resolved to ≤Grade 1 prior to randomization.
- Has had any major surgery within 4 weeks prior to randomization.
- Has low-grade endometrioid, clear cell, mucinous, or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor.
- Has primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤1 month of the last dose of first-line platinum-containing chemotherapy.
- Has not received prior bevacizumab treatment.
- Has been treated with the following prior to randomization: chemotherapy, immunotherapy, investigational agent treatments for disease under study within 28 days before first dose of study drug, radiotherapy not completed at least 2 weeks prior to first dose of study drug, hormonal anticancer therapies within 7 days of first dose of study drug, and systemic, inhaled, or prescription strength topical corticosteroids within 21 days of first dose of study drug.
- Has received wide-field radiation to more than 25% of marrow-bearing areas.
- Has toxicities of prior therapies that have not resolved by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, ≤Grade 1.
- Requires treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses.
- Has a history of severe hypersensitivity or severe reaction to any of the study drugs.
- Is receiving concurrent treatment with mifepristone or other glucocorticoid receptor (GR) modulators.
- Has peripheral neuropathy from any cause >Grade 1.
- Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the screening visit through at least 1 month after the last dose of relacorilant, or 6 months after the last dose of nab-paclitaxel whichever is the longest.
- Has clinically significant uncontrolled condition(s) or condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's safety or participation.
- Has current chronic/active infection with human immunodeficiency virus or current chronic/active infection with hepatitis C virus or hepatitis B virus.
- Has any untreated or symptomatic central nervous system (CNS) metastases.
- Patients with a history of other malignancy within 3 years prior to randomization.
- Is taking a concomitant medication that is a strong cytochrome P450 (CYP)3A inhibitor or strong CYP3A inducer, or that is a substrate of CYP3A with a narrow therapeutic window.
- Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.
- Has received a live vaccine within 30 days prior to the study start date.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2
Patients receive nab-paclitaxel 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1. |
Relacorilant is administered as capsules for oral dosing once daily on the day before, the day of, and the day after nab-paclitaxel administration.
다른 이름들:
Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. |
|
활성 비교기: Nab-paclitaxel 100 mg/m^2
Patients receive nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle. |
Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
기간: Up to 20 months
|
PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions. |
Up to 20 months
|
|
Overall Survival
기간: Up to 32 months
|
Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates. |
Up to 32 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PFS as Assessed by the Investigator
기간: Up to 20 months
|
PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) by RECIST v1.1, or death due to any cause, whichever occurs first. |
Up to 20 months
|
|
Objective Response as Assessed by the Investigator
기간: Up to 20 months
|
Objective response was assessed as the proportion of patients with measurable disease at baseline who attained complete response (CR) or partial response (PR). Confirmation of the response was not required for this outcome measure per RECIST v1.1 criteria for randomized controlled clinical trials. Responses were assessed by imaging, using RECIST v1.1 criteria for target lesions: CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Up to 20 months
|
|
Best Overall Response as Assessed by the Investigator
기간: Up to 20 months
|
Best overall response was assessed as the proportion of patients with at least 1 post Baseline scan who attained CR, PR, stable disease (SD), or PD as best response by RECIST v1.1. |
Up to 20 months
|
|
Duration of Confirmed Responses as Assessed by the Investigator
기간: From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
|
The median duration of response is presented for confirmed responses (CR or PR) per RECIST v1.1. Duration of response was from the first documented and confirmed response to the first objectively documented PD as assessed by the Investigator, or death due to any cause, whichever occurs first. |
From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
|
|
Clinical Benefit Rate at 24 Weeks as Assessed by BICR and the Investigator
기간: 24 weeks
|
Clinical benefit rate was assessed as the proportion of patients who attained CR, PR, or stable disease (SD) for 24 weeks per RECIST v1.1 as assessed by BICR and as assessed by the Investigator. |
24 weeks
|
|
Cancer Antigen (CA)-125 Response
기간: Up to 24 months
|
CA-125 response was assessed per Gynecologic Cancer Intergroup (GCIG) criteria defined as ≥50% reduction in CA-125 from a pretreatment sample and maintained for ≥28 days in patients with a pretreatment sample that is at least twice the upper limit of the reference range within 2 weeks before starting the treatment. In addition, patients who have a CA-125 response and whose CA-125 level fell to within the reference range were classified as CA-125 complete responders. |
Up to 24 months
|
|
Combined Overall Response Rate by RECIST v1.1 and CA-125 Defined by GCIG Criteria
기간: Up to 15 months
|
Combined response was assessed as the proportion of patients with tumor response per RECIST v1.1 assessed by the investigator and for CA-125 response per GCIG criteria. |
Up to 15 months
|
|
Number of Patients With One or More Adverse Events
기간: Up to 22 months
|
Up to 22 months
|
|
|
Number of Patients Who Discontinued the Study Treatment Due to an Adverse Event
기간: Up to 25 months
|
Up to 25 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Adrian Jubb, MBChB, PhD, FRCPath, Corcept Therapeutics
간행물 및 유용한 링크
일반 간행물
- Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study. J Clin Oncol. 2023 Oct 20;41(30):4779-4789. doi: 10.1200/JCO.22.02624. Epub 2023 Jun 26.
- Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balazs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagameri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025 Jun 21;405(10496):2205-2216. doi: 10.1016/S0140-6736(25)01040-2. Epub 2025 Jun 2.
- Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Fagotti A, Gilbert L, Mileshkin L, Quesada S, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Clamp A, Prillaman C, Diakos C, Bagameri A, Leiser AL, Salutari V, Monk BJ, Follana P, McClung E, Carbone V, Slomovitz B, Giudice E, Cannizzaro MC, Gavoille L, Devaux A, Scollo P, Scandurra G, Cassani C, Artioli G, Van Gorp T, Santaballa A, Dreiling LK, Kesner-Hays A, Tudor IC, Jubb AM, Colombo N, Olawaiye AB. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. Lancet. 2026 Apr 18;407(10538):1513-1524. doi: 10.1016/S0140-6736(26)00462-9. Epub 2026 Apr 10.
- Olawaiye AB, Kim JW, Bagameri A, Bishop E, Chudecka-Glaz A, Devaux A, Gladieff L, Gordinier ME, Korach J, McCollum ME, Mileshkin L, Monk BJ, Nicum S, Nogueira-Rodrigues A, Oaknin A, O'Malley DM, Orlando M, Dreiling L, Tudor IC, Lorusso D. Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer. J Gynecol Oncol. 2024 Jul;35(4):e111. doi: 10.3802/jgo.2024.35.e111.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CORT125134-556
- GOG-3073 (기타 식별자: Gynecologic Oncology Group)
- ROSELLA Study 556 (기타 식별자: Corcept Therapeutics)
- ENGOT-OV72 (기타 식별자: European Network of Gynaecological Oncological Trial Groups)
- APGOT-Ov10 (기타 식별자: Asia-Pacific Gynecologic Oncology Trials Group)
- LACOG 0223 (기타 식별자: Latin American Cooperative Oncology Group)
- ANZGOG2221/2023 (기타 식별자: Australia New Zealand Gynaecological Oncology Group)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .